
Current Price | $6.35 | Mkt Cap | $36.0M |
---|---|---|---|
Open | $6.70 | P/E Ratio | -0.54 |
Prev. Close | $6.70 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $6.24 - $6.77 | Volume | 4,888 |
52-Wk Range | $4.65 - $12.75 | Avg. Daily Vol. | 15,148 |
A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.
Current Price | $6.35 | Mkt Cap | $36.0M |
---|---|---|---|
Open | $6.70 | P/E Ratio | -0.54 |
Prev. Close | $6.70 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $6.24 - $6.77 | Volume | 4,888 |
52-Wk Range | $4.65 - $12.75 | Avg. Daily Vol. | 15,148 |
The best Bull and Bear pitches based on recency and number of recommendations.
Clinical trials results for promising cancer drug coming soon.
Threshold is now trading well over cash after trading at less than half cash earlier this year. That can only mean one of two things: a leak of impending positive data from phase II trials of tarloxitinib, or momentum trader games. Given what I've… More
Read the most recent pitches from players about MTEM.
Recs
10000000146
Recs
Clinical trials results for promising cancer drug coming soon.
Recs
Market cap is only $80 million. Approval of their lead compound would push this to a billion plus company.
Find the members with the highest scoring picks in MTEM.
See what the Wall Street professionals think, according to their public statements and filings.